Development of a candidate for a ‘firstin-class’ medicine in a cancer therapy based on YKL-40 active substances. (Q78106): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The main objective of the project is to develop a fine-particle YKL-40 (CHI3L1) inhibitor for cancer therapy and pulmonary fibrosis (‘COPD’) (CHIL).IPF).The...) |
(Created claim: summary (P836): Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The main objective of the project is to develop a small molecular inhibitor of ykl-40 (CHI3L1) for cancer therapy and idiopathic pulmonary fibros...) |
||||||||||||||
| Property / summary | |||||||||||||||
Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The main objective of the project is to develop a small molecular inhibitor of ykl-40 (CHI3L1) for cancer therapy and idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis). IPF). The development of the inhibitor will be the next step in OncoArendi’s long-term strategy to become a world leader in small molecular therapies based on a chitinase platform. The project will use expertise and technologies for the development of chitinase inhibitors and the results of two-year preliminary studies related to the ykl-40 protein. The project will result in a highly active, selective, orally administered ycl-40 inhibitor with an acceptable toxicological profile for the treatment of glioblastomas and other cancers. Glioblastoma multiforme (GBM) remains one of the deadliest cancers and globally unmet medical needs. In order to maximise the therapeutic and commercial potential of the project, based on numerous scientific publications, the leading association will also be explored in animal models of other cancers and IPF to expand the therapeutic potential and market potential of the project. The development of a reserve union will further reduce the technological risk of project failure. Toxicological studies and pharmacological safety assessment in the GLP standard and process chemistry in the GMP standard will provide preparation for development. (English) | |||||||||||||||
| Property / summary: Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The main objective of the project is to develop a small molecular inhibitor of ykl-40 (CHI3L1) for cancer therapy and idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis). IPF). The development of the inhibitor will be the next step in OncoArendi’s long-term strategy to become a world leader in small molecular therapies based on a chitinase platform. The project will use expertise and technologies for the development of chitinase inhibitors and the results of two-year preliminary studies related to the ykl-40 protein. The project will result in a highly active, selective, orally administered ycl-40 inhibitor with an acceptable toxicological profile for the treatment of glioblastomas and other cancers. Glioblastoma multiforme (GBM) remains one of the deadliest cancers and globally unmet medical needs. In order to maximise the therapeutic and commercial potential of the project, based on numerous scientific publications, the leading association will also be explored in animal models of other cancers and IPF to expand the therapeutic potential and market potential of the project. The development of a reserve union will further reduce the technological risk of project failure. Toxicological studies and pharmacological safety assessment in the GLP standard and process chemistry in the GMP standard will provide preparation for development. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The main objective of the project is to develop a small molecular inhibitor of ykl-40 (CHI3L1) for cancer therapy and idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis). IPF). The development of the inhibitor will be the next step in OncoArendi’s long-term strategy to become a world leader in small molecular therapies based on a chitinase platform. The project will use expertise and technologies for the development of chitinase inhibitors and the results of two-year preliminary studies related to the ykl-40 protein. The project will result in a highly active, selective, orally administered ycl-40 inhibitor with an acceptable toxicological profile for the treatment of glioblastomas and other cancers. Glioblastoma multiforme (GBM) remains one of the deadliest cancers and globally unmet medical needs. In order to maximise the therapeutic and commercial potential of the project, based on numerous scientific publications, the leading association will also be explored in animal models of other cancers and IPF to expand the therapeutic potential and market potential of the project. The development of a reserve union will further reduce the technological risk of project failure. Toxicological studies and pharmacological safety assessment in the GLP standard and process chemistry in the GMP standard will provide preparation for development. (English) / qualifier | |||||||||||||||
point in time: 14 October 2020
| |||||||||||||||
Revision as of 11:09, 14 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of a candidate for a ‘firstin-class’ medicine in a cancer therapy based on YKL-40 active substances. |
Project in Poland financed by DG Regio |
Statements
24,382,219.57 zloty
0 references
31,951,381.32 zloty
0 references
76.31 percent
0 references
1 January 2017
0 references
31 December 2022
0 references
ONCOARENDI THERAPEUTICS S.A.
0 references
52°14'1.3"N, 21°4'17.0"E
0 references
Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Głównym celem projektu jest opracowanie drobnocząsteczkowego inhibitora YKL-40 (CHI3L1) do zastosowania w terapii nowotworów i idiopatycznego włóknienia płuc (ang. IPF). Opracowanie inhibitora będzie kolejnym etapem długofalowej strategii osiągniecia przez OncoArendi pozycji światowego lidera w terapiach drobnocząsteczkowych bazujących na platformie chitynazowej. W projekcie wykorzystane będą ekspertyza i technologie rozwijania inhibitorów chitynaz oraz wyniki dwuletnich badań wstępnych związanych z białkiem YKL-40. Rezultatem projektu będzie wysoce aktywny, selektywny, podawany doustnie inhibitor YKL-40 z akceptowalnym profilem toksykologicznym do leczenia glejaków i innych nowotworów. Glejak wielopostaciowy (ang. glioblastoma multiforme, GBM) pozostaje jednym z najbardziej śmiertelnych nowotworów oraz globalnie niezaspokojoną potrzebą medyczną. W celu maksymalizacji terapeutycznego i komercyjnego potencjału projektu, w oparciu o liczne publikacje naukowe, związek wiodący zostanie również zbadany w modelach zwierzęcych innych nowotworów oraz IPF co umożliwi rozszerzenie potencjału terapeutycznego oraz rynkowego projektu. Opracowanie związku rezerwowego dodatkowo ograniczy ryzyko technologiczne niepowodzenia projektu. Badania toksykologiczne i ocena bezpieczeństwa farmakologicznego w standardzie GLP oraz chemia procesowa w standardzie GMP będą stanowiły przygotowanie do prac rozwojowych. (Polish)
0 references
Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The main objective of the project is to develop a small molecular inhibitor of ykl-40 (CHI3L1) for cancer therapy and idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis). IPF). The development of the inhibitor will be the next step in OncoArendi’s long-term strategy to become a world leader in small molecular therapies based on a chitinase platform. The project will use expertise and technologies for the development of chitinase inhibitors and the results of two-year preliminary studies related to the ykl-40 protein. The project will result in a highly active, selective, orally administered ycl-40 inhibitor with an acceptable toxicological profile for the treatment of glioblastomas and other cancers. Glioblastoma multiforme (GBM) remains one of the deadliest cancers and globally unmet medical needs. In order to maximise the therapeutic and commercial potential of the project, based on numerous scientific publications, the leading association will also be explored in animal models of other cancers and IPF to expand the therapeutic potential and market potential of the project. The development of a reserve union will further reduce the technological risk of project failure. Toxicological studies and pharmacological safety assessment in the GLP standard and process chemistry in the GMP standard will provide preparation for development. (English)
14 October 2020
0 references
Identifiers
POIR.01.01.01-00-0552/16
0 references